Sandoz cannot launch its proposed generic Spravato nasal spray before September 2035 after losing a five-day patent trial, while earlier settlements removed Alkem and Hikma from the litigation.
Sandoz cannot launch its proposed generic Spravato nasal spray before September 2035 after losing a five-day patent trial, while earlier settlements removed Alkem and Hikma from the litigation.